{"id":38895,"date":"2025-11-21T12:06:19","date_gmt":"2025-11-21T12:06:19","guid":{"rendered":"https:\/\/cells4life.com\/us\/?p=38895"},"modified":"2026-04-08T15:24:25","modified_gmt":"2026-04-08T15:24:25","slug":"cord-tissue-therapy-charcot-marie-tooth","status":"publish","type":"post","link":"https:\/\/cells4life.com\/us\/2025\/11\/cord-tissue-therapy-charcot-marie-tooth\/","title":{"rendered":"Umbilical Cord Stem Cell Therapy for Charcot-Marie-Tooth Disease to Begin Phase 2 Trial"},"content":{"rendered":"[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; locked=&#8221;off&#8221; sticky_enabled=&#8221;0&#8243;]\n<h3><span style=\"font-weight: 400;\">Key details<\/span><\/h3>\n<ul>\n<li style=\"font-weight: 400;\"><strong>New trial approval:<\/strong> The South Korean Ministry of Food and Drug Safety has approved a Phase 2a trial for a new umbilical cord stem cell therapy to treat Charcot-Marie-Tooth disease (CMT), one of the most commonly inherited nerve diseases.<a href=\"https:\/\/biz.chosun.com\/en\/en-science\/2025\/11\/17\/FC2IA63O6NGQTIE6YWPLAQDSW4\/\" target=\"_blank\" rel=\"noopener\">[1]<\/a><\/li>\n<li style=\"font-weight: 400;\"><strong>Early clinical findings:<\/strong> In a small, early-phase (Phase 1) clinical study, this investigational stem cell therapy was reported to be generally well tolerated, with no serious adverse events observed. Preliminary findings suggested possible improvements in some measures of disease severity and function. However, these results are from a limited, uncontrolled study and further research, including larger controlled trials, is needed to determine whether the treatment is safe and effective.<a href=\"https:\/\/www.newswire.co.kr\/newsRead.php?no=992387\" target=\"_blank\" rel=\"noopener\">[2]<\/a><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06328712\" target=\"_blank\" rel=\"noopener\">[3]<\/a><\/li>\n<li style=\"font-weight: 400;\"><strong>Orphan drug status:<\/strong> The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EN001 for the treatment of CMT, which provides incentives to support development for rare diseases but does not mean the therapy is approved for general use.<a href=\"https:\/\/www.businesswire.com\/news\/home\/20250306675394\/en\/ENCells-EN001-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Charcot-Marie-Tooth-Disease\" target=\"_blank\" rel=\"noopener\">[4]<\/a><\/li>\n<li style=\"font-weight: 400;\"><strong>Future availability:<\/strong> ENCell, the developer, has expressed its intention to continue clinical development after Phase 2a and aims to provide data supporting possible regulatory submission.<a href=\"https:\/\/biz.chosun.com\/en\/en-science\/2025\/11\/17\/FC2IA63O6NGQTIE6YWPLAQDSW4\/\" target=\"_blank\" rel=\"noopener\">[1]<\/a><\/li>\n<\/ul>\n<h3 style=\"font-weight: 400;\">What is Charcot-Marie-Tooth disease?<\/h3>\n<p style=\"font-weight: 400;\">Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that cause damage to the nerves in the arms and legs. It affects both the nerves that control movement (motor nerves) and those that transmit sensations (sensory nerves).<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a><\/p>\n<p style=\"font-weight: 400;\">As one of the most common types of inherited nerve diseases, CMT can be caused by mutations in a wide variety of genes. Depending on the faulty gene, CMT damages either:<\/p>\n<ul>\n<li style=\"font-weight: 400;\">The <strong>myelin sheath<\/strong>, which is the nerves\u2019 protective coat.<\/li>\n<li style=\"font-weight: 400;\">The <strong>axons<\/strong>, which are the nerve fibers themselves.<\/li>\n<\/ul>\n<p style=\"font-weight: 400;\">Both forms of damage significantly impair nerve function.<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a><\/p>\n<p style=\"font-weight: 400;\">As an inherited condition, CMT runs through families. Most forms of CMT, including CMT1, the main form affecting the myelin sheath and the most common,<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a> are inherited in an autosomal dominant pattern. This means someone only needs to get one copy of a faulty gene from one of their parents to develop the condition; inheritance is not connected to the two sex chromosomes, so males and females have equal chances of inheriting the condition. Occasionally, CMT will develop in someone whose family has no prior history, something known as a <em>de novo<\/em> mutation.<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a><\/p>\n<p style=\"font-weight: 400;\">CMT is a progressive condition, meaning symptoms can be subtle at first but will get progressively worse over time. Common symptoms include:<\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Mobility issues:<\/strong> difficulty walking, foot drop (trouble lifting the foot at the ankle), and balance issues.<\/li>\n<li style=\"font-weight: 400;\"><strong>Deformities:<\/strong> highly arched or very flat feet, curled toes, and muscle atrophy (shrinking) in the lower legs.<\/li>\n<li style=\"font-weight: 400;\"><strong>Chronic pain:<\/strong> the strain on the body caused by the problems with walking and posture often leads to muscle and joint pain.<\/li>\n<li style=\"font-weight: 400;\"><strong>Hand issues:<\/strong> as CMT advances, it can begin affecting the hands and arms as well, leading to reduced hand dexterity and strength, which can make daily tasks more difficult.<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a><\/li>\n<\/ul>\n<p style=\"font-weight: 400;\">There is currently no cure for CMT. Treatment is limited to supportive care and symptom management, including physical therapy, occupational therapy, orthopedic devices to support weakened limbs, walking aids such as walkers or wheelchairs, pain medication, and surgery to correct deformities.<a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\">[5]<\/a><\/p>\n<h3 style=\"font-weight: 400;\">How could umbilical cord stem cells help treat CMT?<\/h3>\n<p style=\"font-weight: 400;\">The stem cell therapy being trialed for CMT is based on mesenchymal stem cells (MSCs) derived from the Wharton\u2019s jelly found in umbilical cord tissue.<a href=\"https:\/\/www.encellinc.com\/en\/sub\/rnd\/pipeline.asp\" target=\"_blank\" rel=\"noopener\">[6]<\/a> Wharton\u2019s jelly is a rich source of powerful MSCs, which, due to their young age, multiply more effectively than MSCs derived from adult tissues such as the bone marrow or fat.<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16410387\/\" target=\"_blank\" rel=\"noopener\">[7]<\/a><a href=\"https:\/\/www.nature.com\/articles\/s41392-025-02313-9\" target=\"_blank\" rel=\"noopener\">[8]<\/a> They can reduce inflammation, modulate the immune system, and promote healing and regeneration.<a href=\"https:\/\/www.mdpi.com\/1422-0067\/14\/6\/11692\" target=\"_blank\" rel=\"noopener\">[9]<\/a><\/p>\n<p style=\"font-weight: 400;\">The therapeutic mechanism involves:<\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Schwann cell support:<\/strong> In laboratory studies using cells derived from patients with Charcot-Marie-Tooth disease type 1A (CMT1A), Wharton\u2019s jelly\u2013derived mesenchymal stem cells (WJ-MSCs) were shown to support Schwann cell growth. This effect was more pronounced when combined with insulin, suggesting a potential synergistic interaction under experimental conditions.<\/li>\n<li style=\"font-weight: 400;\"><strong>Myelin-related effects:<\/strong> The study observed changes in markers associated with myelination in treated Schwann cells in vitro. While these findings indicate a possible supportive role in myelin biology, they are based on early-stage laboratory research.<\/li>\n<li style=\"font-weight: 400;\"><strong>Functional improvements:<\/strong> In a mouse model of CMT1A, treatment with WJ-MSCs in combination with insulin was associated with improvements in motor function compared to untreated animals.<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0969996124003279\" target=\"_blank\" rel=\"noopener\">[10]<\/a><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">What do the results of the phase 1 trial for CMT show?<\/span><\/h3>\n<p style=\"font-weight: 400;\">Data from a first-in-human Phase 1 trial of an investigational umbilical cord\u2013derived mesenchymal stem cell therapy (EN001) for Charcot-Marie-Tooth disease type 1A (CMT1A) suggest that the treatment was generally well tolerated, with exploratory findings indicating potential effects on disease-related measures.<\/p>\n<p style=\"font-weight: 400;\">The study included nine patients in a dose-escalation design (three receiving a low dose and six a high dose), with outcomes assessed over 16 weeks.<\/p>\n<p style=\"font-weight: 400;\">No dose-limiting toxicity, serious adverse events, or infusion-related reactions were reported, supporting a favorable safety profile in this small cohort.<\/p>\n<p style=\"font-weight: 400;\">Exploratory efficacy measures showed a reduction in disease severity, as assessed by the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNSv2), with an average decrease of 2.89 points after 16 weeks. A greater reduction was observed in the high-dose group (3.50 points). While these findings reached statistical significance, they should be interpreted with caution given the study\u2019s small size and early-phase design.<\/p>\n<p style=\"font-weight: 400;\">Changes were also observed in functional and clinical assessments, including walking tests, disability scales, and nerve conduction studies, particularly in the high-dose group. These results are preliminary and require confirmation in larger, controlled trials.<a href=\"https:\/\/www.newswire.co.kr\/newsRead.php?no=992387\" target=\"_blank\" rel=\"noopener\">[2]<\/a><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06328712\" target=\"_blank\" rel=\"noopener\">[3]<\/a><\/p>\n<p style=\"font-weight: 400;\">Following this study, EN001 received orphan drug designation from the U.S. Food and Drug Administration (FDA). Further clinical development is ongoing, including a Phase 1b\/2a trial to better understand safety and potential efficacy.<a href=\"https:\/\/www.businesswire.com\/news\/home\/20250306675394\/en\/ENCells-EN001-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Charcot-Marie-Tooth-Disease\" target=\"_blank\" rel=\"noopener\">[4]<\/a><\/p>\n<h3><span style=\"font-weight: 400;\">Why is stem cell banking so important?<\/span><\/h3>\n<p style=\"font-weight: 400;\">Stem cell banking involves collecting and storing stem cells from your baby\u2019s umbilical cord at birth. These cells are currently used in a limited number of established medical treatments, and research is ongoing to understand their potential in other areas.<\/p>\n<p style=\"font-weight: 400;\">Storing your child\u2019s stem cells does not guarantee that they will be suitable or needed for future use. However, it ensures that a matched sample is available should it be required and clinically appropriate.<\/p>\n<p style=\"font-weight: 400;\">Some families choose to store these cells as a way of keeping this option available for the future.<\/p>\n<p style=\"font-weight: 400;\">To learn more about umbilical cord stem cells and how you can preserve them, fill in the form below to request your free info kit.<\/p>\n<h3 style=\"font-weight: 400;\">References<\/h3>\n<p><a href=\"https:\/\/biz.chosun.com\/en\/en-science\/2025\/11\/17\/FC2IA63O6NGQTIE6YWPLAQDSW4\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[1] CHOSUNBIZ (2025).\u00a0<i>ENCell advances stem cell therapy for Charcot\u2013Marie\u2013Tooth with phase 2a approval<\/i>. https:\/\/biz.chosun.com\/en\/en-science\/2025\/11\/17\/FC2IA63O6NGQTIE6YWPLAQDSW4\/<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.newswire.co.kr\/newsRead.php?no=992387\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[2] Newswire (2024). <i>ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference<\/i>. https:\/\/www.newswire.co.kr\/newsRead.php?no=992387<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06328712\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[3] Clinicaltrials.gov (2025). <em>Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A.<\/em> https:\/\/www.clinicaltrials.gov\/study\/NCT06328712<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250306675394\/en\/ENCells-EN001-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Charcot-Marie-Tooth-Disease\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[4] Business Wire (2025).\u00a0<em>EnCell&#8217;s EN001 Receives Orphan Drug Designation from the U.S. FDA for Charcot-Marie-Tooth Disease.<\/em> https:\/\/www.businesswire.com\/news\/home\/20250306675394\/en\/ENCells-EN001-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Charcot-Marie-Tooth-Disease<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[5] NHS (2019). <i>Charcot-Marie-Tooth disease<\/i>. https:\/\/www.nhs.uk\/conditions\/charcot-marie-tooth-disease\/<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.encellinc.com\/en\/sub\/rnd\/pipeline.asp\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[6] ENCell. <i>Pipeline<\/i>. https:\/\/www.encellinc.com\/en\/sub\/rnd\/pipeline.asp<\/span><\/a><\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16410387\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[7] Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006 May;24(5):1294-301. doi: 10.1634\/stemcells.2005-0342. Epub 2006 Jan 12. PMID: 16410387<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41392-025-02313-9\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[8] Han, X., Liao, R., Li, X.\u00a0<em>et al.<\/em>\u00a0Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.\u00a0<em>Sig Transduct Target Ther<\/em>\u00a0<strong>10<\/strong>, 262 (2025). https:\/\/doi.org\/10.1038\/s41392-025-02313-9<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/1422-0067\/14\/6\/11692\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[9] Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton&#8217;s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390\/ijms140611692. PMID: 23727936; PMCID: PMC3709752.<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0969996124003279\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[10] Oh SJ, Kim H, Park SE, Kim JH, Kim YJ, Choi SJ, Oh SY, Jeon HB, Chang JW. Synergistic effect of Wharton&#8217;s jelly-derived mesenchymal stem cells and insulin on Schwann cell proliferation in Charcot-Marie-Tooth disease type 1A treatment. Neurobiol Dis. 2024 Dec;203:106725. doi: 10.1016\/j.nbd.2024.106725. Epub 2024 Nov 12. PMID: 39536952<\/span><\/a><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_class=&#8221;down-arrow&#8221; _builder_version=&#8221;4.27.4&#8243; background_color=&#8221;#bd144f&#8221; custom_padding=&#8221;0px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;RWP&#8221; module_id=&#8221;request-welcome-pack&#8221; _builder_version=&#8221;4.27.4&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; background_layout=&#8221;dark&#8221; use_border_color=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>FIND OUT MORE, REQUEST YOUR FREE INFO KIT TODAY<\/h3>\n<p>All you need to know to make an informed decision.<\/p>\n<p>Provide your contact details to request:<\/p>\n<p>&#8211; Complete Info Kit and your Guide to Cord Blood Banking<br \/>&#8211; Information via email<br \/>&#8211; Contact from our specialist advisors<\/p>\n<p>&nbsp;<\/p>\n\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f14118-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"14118\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/us\/wp-json\/wp\/v2\/posts\/38895#wpcf7-f14118-o1\" method=\"post\" class=\"wpcf7-form init\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"14118\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.5\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f14118-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<p>Title* <span class=\"wpcf7-form-control-wrap\" data-name=\"salutation\"><select class=\"wpcf7-form-control wpcf7-select wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" name=\"salutation\"><option value=\"- Select -\">- Select -<\/option><option value=\"Mr\">Mr<\/option><option value=\"Mrs\">Mrs<\/option><option value=\"Miss\">Miss<\/option><option value=\"Ms\">Ms<\/option><option value=\"Dr\">Dr<\/option><option value=\"Prof\">Prof<\/option><option value=\"Sir\">Sir<\/option><option value=\"Madam\">Madam<\/option><option value=\"Other\">Other<\/option><\/select><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"first_name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required c4l-capitalize\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name(s)*\" value=\"\" type=\"text\" name=\"first_name\" \/><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"last_name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required c4l-capitalize\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"last_name\" \/><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"email1\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email email1_3838\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email Address*\" value=\"\" type=\"email\" name=\"email1\" \/><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"email_hp\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-text wpcf7-validates-as-email c4l-hp\" aria-invalid=\"false\" placeholder=\"Alternate Email Address\" value=\"\" type=\"email\" name=\"email_hp\" \/><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"phone_mobile\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Phone Number*\" value=\"\" type=\"text\" name=\"phone_mobile\" \/><\/span>\n<\/p>\n<p>Due Date* <span class=\"date-row-cf7-custom\"><span class=\"wpcf7-form-control-wrap\" data-name=\"delivery_month\"><select class=\"wpcf7-form-control wpcf7-select wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" name=\"delivery_month\"><option value=\"\">Month<\/option><option value=\"01\">Jan<\/option><option value=\"02\">Feb<\/option><option value=\"03\">Mar<\/option><option value=\"04\">Apr<\/option><option value=\"05\">May<\/option><option value=\"06\">Jun<\/option><option value=\"07\">Jul<\/option><option value=\"08\">Aug<\/option><option value=\"09\">Sep<\/option><option value=\"10\">Oct<\/option><option value=\"11\">Nov<\/option><option value=\"12\">Dec<\/option><\/select><\/span><span class=\"wpcf7-form-control-wrap\" data-name=\"delivery_day\"><select class=\"wpcf7-form-control wpcf7-select wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" name=\"delivery_day\"><option value=\"\">Day<\/option><option value=\"01\">01<\/option><option value=\"02\">02<\/option><option value=\"03\">03<\/option><option value=\"04\">04<\/option><option value=\"05\">05<\/option><option value=\"06\">06<\/option><option value=\"07\">07<\/option><option value=\"08\">08<\/option><option value=\"09\">09<\/option><option value=\"10\">10<\/option><option value=\"11\">11<\/option><option value=\"12\">12<\/option><option value=\"13\">13<\/option><option value=\"14\">14<\/option><option value=\"15\">15<\/option><option value=\"16\">16<\/option><option value=\"17\">17<\/option><option value=\"18\">18<\/option><option value=\"19\">19<\/option><option value=\"20\">20<\/option><option value=\"21\">21<\/option><option value=\"22\">22<\/option><option value=\"23\">23<\/option><option value=\"24\">24<\/option><option value=\"25\">25<\/option><option value=\"26\">26<\/option><option value=\"27\">27<\/option><option value=\"28\">28<\/option><option value=\"29\">29<\/option><option value=\"30\">30<\/option><option value=\"31\">31<\/option><\/select><\/span><span class=\"wpcf7-form-control-wrap\" data-name=\"delivery_year\"><select class=\"wpcf7-form-control wpcf7-select wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" name=\"delivery_year\"><option value=\"\">Year<\/option><option value=\"2026\">2026<\/option><option value=\"2027\">2027<\/option><\/select><\/span><\/span>\n<\/p>\n<p><span class=\"wpcf7-form-control-wrap\" data-name=\"primary_address_postalcode\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text c4l-uppercase\" aria-invalid=\"false\" placeholder=\"Zip Code\" value=\"\" type=\"text\" name=\"primary_address_postalcode\" \/><\/span>\n<\/p>\n<p id=\"cf7tosugar_by_post\">By mail?<span class=\"wpcf7-form-control-wrap\" data-name=\"welcome_pack_by_post_c\"><span class=\"wpcf7-form-control wpcf7-checkbox\"><span class=\"wpcf7-list-item first last\"><input type=\"checkbox\" name=\"welcome_pack_by_post_c[]\" value=\"Yes\" \/><span class=\"wpcf7-list-item-label\">Yes<\/span><\/span><\/span><\/span>\n<\/p>\n<p class=\"cf7tosugar_address\"><span class=\"wpcf7-form-control-wrap\" data-name=\"primary_address_street\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text c4l-capitalize\" aria-invalid=\"false\" placeholder=\"Address 1\" value=\"\" type=\"text\" name=\"primary_address_street\" \/><\/span>\n<\/p>\n<p class=\"cf7tosugar_address\"><span class=\"wpcf7-form-control-wrap\" data-name=\"primary_address_city\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text c4l-capitalize\" aria-invalid=\"false\" placeholder=\"Address 2\" value=\"\" type=\"text\" name=\"primary_address_city\" \/><\/span>\n<\/p>\n<p class=\"cf7tosugar_address\"><span class=\"wpcf7-form-control-wrap\" data-name=\"primary_address_state\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text c4l-capitalize\" aria-invalid=\"false\" placeholder=\"State\" value=\"\" type=\"text\" name=\"primary_address_state\" \/><\/span>\n<\/p>\n<p class=\"cf7tosugar_address\"><span class=\"wpcf7-form-control-wrap\" data-name=\"primary_address_country\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text c4l-capitalize\" aria-invalid=\"false\" placeholder=\"Country\" value=\"\" type=\"text\" name=\"primary_address_country\" \/><\/span>\n<\/p>\n<p><input class=\"wpcf7-form-control wpcf7-submit has-spinner wpcf7-button c4l-button-dark gtm-rwp-onpage\" type=\"submit\" value=\"REQUEST\" \/>\n<\/p>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"us\" type=\"hidden\" name=\"webform_site_c\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"true\" type=\"hidden\" name=\"sugar_crm_lead\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"76dbb9e8-4c86-d341-0772-689602ea5afc\" type=\"hidden\" name=\"campaign_id\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"e4987368-af56-291e-0908-4e82dbf541c4\" type=\"hidden\" name=\"assigned_user_id\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"e4987368-af56-291e-0908-4e82dbf541c4\" type=\"hidden\" name=\"created_by\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"rwp\" type=\"hidden\" name=\"lead_source\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"{EXT_REFERER}\" type=\"hidden\" name=\"webform_referrer_url_c\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"{COOKIE:_#uid}\" type=\"hidden\" name=\"webform_contact_id_c\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"request-welcome-pack\" type=\"hidden\" name=\"originating_web_form_c\" \/>\n<input class=\"wpcf7-form-control wpcf7-hidden\" value=\"{IP_ADDRESS}\" type=\"hidden\" name=\"webform_ip_address_c\" \/><input type='hidden' class='wpcf7-pum' value='{\"closepopup\":false,\"closedelay\":0,\"openpopup\":false,\"openpopup_id\":0}' \/><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;LAM bio block&#8221; module_class=&#8221;down-arrow&#8221; _builder_version=&#8221;4.27.5&#8243; global_colors_info=&#8221;{}&#8221; locked=&#8221;off&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_team_member name=&#8221;Lesley-Ann Martin, PhD&#8221; position=&#8221;Chief Scientific Officer at Cells4Life&#8221; image_url=&#8221;https:\/\/cells4life.com\/wp-content\/uploads\/2019\/08\/lesley-ann.png&#8221; admin_label=&#8221;Person&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_css_free_form=&#8221;selector {||  background: #e3f2f8;||  border-radius: 30px;||  padding: 20px;||}||selector img {||  height: 100px;||  width: 100px;||}&#8221; global_colors_info=&#8221;{}&#8221;]\n<p style=\"font-weight: 400;\">Dr. Martin holds a PhD in Molecular Biology from the University of Reading and has extensive research experience at the Institute of Cancer Research. She oversees all scientific and laboratory operations at Cells4Life.<\/p>\n[\/et_pb_team_member][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>Key details New trial approval: The South Korean Ministry of Food and Drug Safety has approved a Phase 2a trial for a new umbilical cord stem cell therapy to treat Charcot-Marie-Tooth disease (CMT), one of the most commonly inherited nerve diseases.[1] Early clinical findings: In a small, early-phase (Phase 1) clinical study, this investigational stem [&hellip;]<\/p>\n","protected":false},"author":1447,"featured_media":38901,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Most people know what it\u2019s like to feel sadness. But when feeling down persists for weeks, or even months, it can be a sign of a mental health condition, like depression.<\/p><p>Although today people are well versed and more understanding of depression, some sufferers still find it difficult to find treatments.<\/p><h3>What is depression?<\/h3><p>Depression is a common mental health condition. It is characterised by low mood, feelings of hopelessness, losing interest in things which previously brought a sense of enjoyment, and feeling tearful.<\/p><p>Depression can also manifest in physical ways. Sleeping poorly, feeling tired, experiencing aches, pains, a diminished appetite, and decreased libido can all be impacts of depression. The symptoms range from mild to severe. In mild cases, a persistent low mood may be the cause, while severe cases may result in suicidal feelings or a desire to self harm <a href=\"https:\/\/www.nhs.uk\/mental-health\/conditions\/depression-in-adults\/overview\/\">[1]<\/a>.<\/p><p>Sometimes the causes of depression can be obvious, such as a bereavement or a traumatic event. Other times there might be no known cause, although family history could be the reason. Whatever the reason, once a person has identified they may be depressed, they should go and see their GP.<\/p><h3>What treatments are available?<\/h3><p>There are a plethora of treatments for depression that a doctor can prescribe, from talking therapies to pharmaceutical medications to exercise and more. Sometimes the GP may recommend one treatment or a combination of treatments but they will help support patients and signpost them to services which can bolster their support network.<\/p><p>The good news is that depression is among the most treatable mental health disorders.\u00a0 Between 80% and 90% percent of people with depression eventually respond well to treatment. Almost all patients gain some relief from their symptoms <a href=\"https:\/\/www.psychiatry.org\/patients-families\/depression\/what-is-depression#:~:text=Depression%20is%20among%20the%20most,some%20relief%20from%20their%20symptoms.\">[2]<\/a>.<\/p><h3>Treatment Resistant Depression<\/h3><p>For those with major depressive disorder, however, treatment can be harder to find. With up to one third of adults with the condition failing to respond to treatment, new avenues and treatments are being sought.<\/p><p>\u201cAlthough there is some disagreement as to how to define treatment-resistant depression, a patient is generally considered to have it if the individual hasn\u2019t responded to adequate doses of two different antidepressants taken for a sufficient duration of time, which is usually six weeks,\u201d explains Jaskaran Singh, M.D., Senior Director of Neuroscience, Janssen Pharmaceuticals <a href=\"https:\/\/www.jnj.com\/health-and-wellness\/4-facts-about-treatment-resistant-depression\">[3]<\/a>.<\/p><p>The theory that depression may have causes currently unknown by scientists is one theory researchers are exploring to try and combat resistance to treatment.<\/p><p>\u201cOne of the more modern theories is that depression creates inflammation in the brain, or that inflammation in the brain creates depression. Traditional antidepressants only affect neurotransmitters, so this may be why some patients don\u2019t respond to them.\u201d\u00a0 says Alexander Papp, M.D., a psychiatrist at UC San Diego Health <a href=\"https:\/\/www.jnj.com\/health-and-wellness\/4-facts-about-treatment-resistant-depression\">[4]<\/a>.<\/p><p>Whether or not this is the case, researchers are still trying to find solutions to Treatment Resistant Depression.<\/p><h3>The Potential of Cord Blood Therapy<\/h3><p>One study using umbilical cord blood cells delivered promising results. The study administered concentrated umbilical cord blood cells at a dose of 250 million cells via weekly injections over 4 weeks with 1 week intervals, to women who suffered with Treatment Resistant Depression.\u00a0 The results were tested against a control group who received a placebo.<\/p><p>The study found that the therapeutic potential of umbilical cord blood cell concentrate can be used to overcome treatment resistance formed in depressive patients <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7087609\/\">[5]<\/a>. Other studies have also found that cellular therapies may have a role in combating Treatment Resistant Depression <a href=\"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/814\">[6]<\/a> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8474995\/\">[7]<\/a>.<\/p><p>These studies give hope for finding new treatments. With the help of umbilical cord blood cells, those suffering from Treatment Resistant Depression may one day find relief from the debilitating illness affecting their day to day lives.<\/p><p>If you think you may be suffering from depression please speak to your GP.<\/p><p>\u00a0<\/p><p><strong>Organisations who can help if you need someone to talk to:<\/strong><\/p><p><strong>Samaritans: Call 116 123 - It\u2019s FREE and available 24\/7<\/strong><\/p><p><strong>Shout 85258: text SHOUT to 85258 - It\u2019s FREE and available 24\/7<\/strong><\/p><p><strong>CALM: Call 0800 58 58 58 or use their webchat <a href=\"https:\/\/www.thecalmzone.net\/get-support#open-calmbot\">here<\/a>.\u00a0 The helpline and webchat are both open 5pm to midnight, 365 days a year.<\/strong><\/p><p>\u00a0<\/p>","_et_gb_content_width":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[55,9281,60,87,9280,76],"tags":[9252,9248],"class_list":["post-38895","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-neurological-disorders","category-news","category-stem-cell-news","category-stem-cell-therapies","category-uses-for-cord-tissue","tag-blog","tag-stem-cell-therapy"],"_links":{"self":[{"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/posts\/38895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/users\/1447"}],"replies":[{"embeddable":true,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/comments?post=38895"}],"version-history":[{"count":5,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/posts\/38895\/revisions"}],"predecessor-version":[{"id":39248,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/posts\/38895\/revisions\/39248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/media\/38901"}],"wp:attachment":[{"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/media?parent=38895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/categories?post=38895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cells4life.com\/us\/wp-json\/wp\/v2\/tags?post=38895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}